DIPG-27. OPTIMIZING CLINICAL TRIAL DESIGN: PHARMACOKINETICS OF MARIZOMIB AND PANOBINOSTAT IN A NON-HUMAN PRIMATE MODEL

BACKGROUND: Pre-clinical determination of disease-specific activity, effective dosing, safety, pharmacokinetics, and CNS delivery can optimize clinical trial designs. The proteasome inhibitor, marizomib, together with the HDAC inhibitor, panobinostat, is active and synergistic in pre-clinical DIPG s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Warren, Katherine, Shankarappa, Priya, Peer, Cody, Garcia, Rafael Cruz, Monje-Deisseroth, Michelle, Figg, W Doug, McCully, Cynthia Lester
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Diffuse Intrinsic Pontine Glioma (DIPG)
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477305/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.048
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia